Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Raymond James analyst Thomas Deal initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $6.
Raymond James analyst Thomas Deal initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $6.